ImmunoCellular Therapeutics, Ltd Announces Research Agreement with George Mason University for Detection of Certain Cancers

LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) (IMUC), a biotechnology company, today announced that the company has signed a research agreement with George Mason University for the development of a blood test to detect small cell lung cancer and pancreatic cancer using IMUC’s monoclonal antibody technology. The blood-based test would be designed to look for certain markers for the cancers potentially allowing for early detection of these cancers as well as assisting the selection of patients most likely to respond to the company’s monoclonal antibody therapy, ICT-109.

Back to news